Researchers at the EADV Congress found 39% of 575 GLP-1 users had nails lifting from the nail bed, versus 9% of non-users. Authors say it's a link, not proof.
Recap by typeshit. Full story at North Wales Live.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
Presented at EASD, the analysis put Foundayo 17.2 mg ahead by 1.5% in weight loss and 0.3% in A1C at 52 weeks, though no head-to-head trial was run.
The OCTANE analysis of 194 Ro telehealth patients was presented at EASD 2026. It had no comparison group, and patients who stopped treatment were left out.
Loading…